


FIG. 1A



Grupos	DOSIS DE TUMOR	TRATAMIENTO						Ratones
		Régimen de vacunación	células SQZ	Dosis/ratón	Frecuencia	Coinyección	Dosis/ratón	
A	50K TC-1	N/A	Sin tratar	N/A				10
B		TERAPÉUTICO	E7+CpG SQZ	CEB (5M),REFUER (5M)		Dia +4,+7	Ninguno	
C				CEB (2, 5M) REFUER (2,5M)				
D				CEB (5 M) REFUER (1M)				
E				CEB (2,5 M) REFUER (1 M)				

FIG. 1B




FIG. 2A



Grupos		Ratones	Tratamiento	Rendim.
A	Sin tratar	3	5M células/ratón	Día +7 Tinción tetramero (esplenocitos). ICS esplenocitos)
B	Endo E7 43-77(Serina)	5	adyuvante p/ todos los grupos CpG200 ug (Endo o SQZ)	
C	SQZ ⁻ E7 43-77 (Serina)	5		
D	Endo E7 43-77(Cisteína)	5	Antígeno p/ todos los grupos 10 uM SLP+10uM MSA SQZ ⁻	
E	SQZ ⁻ E7 43-77 (Cisteína)	5		

FIG. 2B




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG.6 (Continuación)




FIG. 7A

GRUPOS		# ratones	DOSIS
A	Sin tratar	3	Cebaz 5M células / ratón
B	LMW poli I:C + OVA SQZ	5	
C	LMW poli I:C + OVA Endo	5	
D	HMW poli I:C + OVA SQZ	5	
E	HMW poli I:C + OVA Endo	5	
F	CpG + OVA SQZ	5	




FIG. 7B




FIG. 8A

Grupos		ratones	tratamiento
A	sin tratar	3	cebar 5M células/ Ratón
B	Endo OVA+CpG (200ug/mL)	5	
C	SQZ OVA+CpG (200ug/mL)	5	
D	Endo OVA+CpG (100ug/mL)	5	
E	SQZ OVA+CpG (100ug/mL)	5	
F	Endo OVA+CpG (50ug/mL)	5	
G	SQZ OVA+CpG (50ug/mL)	5	




FIG. 8B




FIG. 9A

Grupos		ratones	tratamiento
A	sin tratar	3	5M células/ratón
B	Endo OVA (Día 0) +inyección CpG (día 0)	5	
C	SQZ OVA + CpG (Día 0) + Inyección CpG (Día 0)	5	
D	Endo OVA (Día 0) + Inyección CpG (Día 1)	5	CpG 25 ug/ratón
E	SQZ OVA + CpG (Día 0) + Inyección CpG (Día 1)	5	
F	Endo OVA (Día 0) + Inyección CpG (Día 2)	5	OVA SQZ (400 ug/mL)
G	SQZ OVA + CpG (Día 0) + Inyección CpG (Día 2)	5	
H	OVA +CpG (Día 0)	3	




FIG. 9B





FIG. 10A



Grupos	Tratamiento				Ratones	
	Células T SQZd	Dosis/ratón	Coinyección	Dosis/ratón.		
A	sin tratar	5M	N/A	N/A	10	
B	E7 SQZ'		CpG	25 ug		
C			IFNα	10K IU		
D	E7+CpG SQZ'		Ninguno			
E	CpG		25 ug			
F	IFNα		10K IU			

FIG. 10B




FIG. 10C




FIG. 10D





FIG. 11A



Grupos	Tratamiento	# célulasx10E6 (T)	Células TC-1 x10E5	# Rato- nes	Tratamiento
A	sin tratar	0	0.5	10	Dia 7 y 14
B	Células T E7+CpG SQZ	5		10	
C	Células T E7+CpG Endo	5		5	
D	Células T E7 SQZ	5		5	
E	Células T CpG SPZ	5		5	
F	Células T E7+ E6+SQZ	5		10	
G	E6+CpG SQZ T	5		9	

FIG. 11B




FIG. 11C





FIG. 12A



Grupo	N° de ratones	Dosis de células T	Antígeno (SLP)	CpG durante SQZ	MSA	CpG coinyectado
A: Sin Ag	10	n/a	n/a	n/a	n/a	n/a
B: CpG Inyectado	10	n/a	n/a	n/a	n/a	25ug/ratón
C: SQZ (SPL solamente)	10	5M	20uM E7	n/a	20uM	25ug/ratón
D: SQZ (SLP + CpG)	8	5M	20uM E7	200ug/ml	20uM	n/a

FIG. 12B




FIG. 13



Grupos:

- A) Inyección de CpG
- B) Inyección de IFN alfa
- C) SQZ (sin adyuvante)
- D) SQZ + CpG
- E) SQZ + IFN α





FIG. 14A



Grupos	Dosis del tumor	Tratamiento						Ratones
		Régimen de vacunación	Células SQZ	dosis/ratón	frecuencia	coinyección	dosis/ratón	
A	50K TC-1	N/A	sin tratar	N/A				10
B		TERAPEUTICO	7+CpG SQZ'd	5M	día+4,+7,+11	Ninguno		
C					día+7,+14,+21			
D					día +7,+14			

FIG. 14B




FIG. 15




FIG. 16




FIG. 17




FIG. 18A




FIG. 18B




FIG. 19




FIG. 20




FIG. 21




FIG. 22

